Burnham Announces License Agreement with Johnson & Johnson Pharmaceutical Research & Development
Date Posted: Wednesday, January 14, 2009
Burnham Institute for Medical Research (Burnham) has signed an assay development and license agreement with Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD). The agreement is Burnham's first broad-based partnership with a large pharmaceutical company.
Under this multi-year agreement, Burnham will provide J&JPRD with access to high-throughput assay screening technologies to investigate certain drug targets for inflammatory diseases. Financial terms were not disclosed.
"This collaboration offers great synergies," said Dr. John Reed, Burnham President and CEO, Professor and Donald Bren Presidential Chair. "Burnham has great expertise in finding new targets and screening compounds to identify chemical leads, and I believe this collaboration will foster the discovery of drug products with real clinical potential."
Further Information: http://www.burnham.org/
Related news from our archive
NextBio Life Science Search Engine Licensed by the Burnham Institute to Speed Research Across Public and Private Data
Under the agreement, every scientist at the Burnham Institute will gain access to the NextBio life science search engine.
Mechanism by which Signaling Pathways Regulate Growth and Differentiation of Adult Muscle Stem Cells Revealed
Researchers shows how two signaling pathways work together to assemble components of the protein complexes responsible for muscle-specific transcription.
AIDS Interferes with Stem Cells in the Brain
Burnham scientists discovered how HIV/AIDS disrupts the normal replication of stem cells in the adult brain, preventing new nerve cells from forming.
CIRM Awards $3.79 Million to Burnham Institute
Funding will support shared research laboratories and expanded facilities for training in human embryonic stem cell research.